STOCK TITAN

Coherus BioSciences, Inc. - CHRS STOCK NEWS

Welcome to our dedicated page for Coherus BioSciences news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus BioSciences stock.

Coherus BioSciences, Inc. (NASDAQ: CHRS) is a leading commercial-stage biopharmaceutical company dedicated to improving patient access to high-quality, life-changing biologic medicines. Established in 2010 and headquartered in the San Francisco Bay Area, Coherus specializes in developing biosimilars and innovative immuno-oncology therapies to treat various chronic and life-threatening diseases.

Coherus' core business revolves around providing biosimilar therapeutics that are designed to replace existing branded biologics, thereby reducing healthcare costs. The company's biosimilar portfolio includes FDA-approved products like UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), which is set to launch in the US in 2023. These products help manage conditions such as cancer and autoimmune diseases, expanding patient access to essential treatments.

Recently, Coherus completed the divestiture of its ophthalmology franchise, CIMERLI®, to Sandoz, Inc. for $170 million. This move allows Coherus to focus more intently on its immuno-oncology pipeline, which includes the promotion of LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor approved for nasopharyngeal carcinoma. The company's strategy includes advancing its novel immuno-oncology candidates like CHS-114 and CHS-1000, which are in various stages of clinical development targeting solid tumors.

Financially, Coherus is leveraging the revenue from its biosimilar products to fund its immuno-oncology research and development. The company collaborates with global pharmaceutical partners across Europe, Asia, and Latin America, enhancing its market presence and resource capabilities.

Key updates include the successful preclinical data presentation for CHS-1000 at the 2024 AACR Annual Meeting, showcasing its potential to reverse immunosuppression in the tumor microenvironment. Moreover, the Cancer Research Institute (CRI) has selected LOQTORZI for combination studies to explore its efficacy in drug-resistant cancers, further solidifying Coherus' commitment to pioneering cancer therapy advancements.

Led by a team of seasoned industry veterans, Coherus BioSciences aims to become a global leader in the biosimilar and immuno-oncology markets, continually striving to develop therapies that improve patient outcomes and broaden access to high-quality medical treatments.

Rhea-AI Summary

The FDA has accepted Coherus BioSciences’ Biologics License Application (BLA) for toripalimab, targeted for patients with advanced nasopharyngeal carcinoma (NPC). A decision is expected by December 23, 2022. Toripalimab aims to be the first approved immunotherapy for NPC in the U.S. and is crucial for patients facing unmet medical needs. The anticipated launch is set for Q1 2023, pending FDA approval. The drug is supported by positive Phase 2 and 3 clinical trial results, emphasizing its potential as a key oncology product for Coherus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
-
Rhea-AI Summary

Coherus BioSciences, Inc. (CHRS) announced the granting of stock options to 16 new employees as of June 16, 2022. A total of 409,000 shares were made available, with a per-share exercise price of $5.86, the closing price on the grant date. The options include 200,000 shares for a Chief level executive and 45,000 shares for a Vice President, while 14 non-officer employees received a combined total of 164,000 shares. This initiative is part of the 2016 Employment Commencement Incentive Plan aimed at attracting new talent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.13%
Tags
none
-
Rhea-AI Summary

Coherus Biosciences has appointed Dr. Jill O’Donnell-Tormey, a leader in cancer immunotherapy, to its Board of Directors. With over 30 years at the Cancer Research Institute, she will also serve on the Nominating and Corporate Governance Committee. CEO Denny Lanfear emphasized her experience in advancing immunotherapies. Dr. O’Donnell-Tormey expressed enthusiasm for helping Coherus deliver new cancer treatments. Coherus is focused on building a robust immuno-oncology franchise, with upcoming product launches including YUSIMRY™, aiming to enhance patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
management
Rhea-AI Summary

Coherus BioSciences (Nasdaq: CHRS) announced its participation in three investor conferences in May 2022. The BofA Securities 2022 Healthcare Conference will occur on May 12 at 3:00 p.m. ET, followed by the UBS Global Healthcare Conference on May 24 at 2:00 p.m. ET, and the H.C. Wainwright Global Investment Conference on May 25 at 9:00 a.m. ET. Audio webcasts of each presentation will be available on the Coherus investors’ page, with archived access for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
conferences
-
Rhea-AI Summary

Coherus BioSciences (CHRS) reported Q1 2022 net sales of UDENYCA® at $60.1 million, down from $83 million in Q1 2021, attributed to increased competition. The company plans to resubmit the toripalimab BLA by mid-summer after addressing a complete response letter from the FDA. CIMERLI™ is advancing, with an action date set for August 2, 2022. R&D and SG&A expense guidance has been reduced by $20 million to $395-$430 million for the year. Coherus reported a net loss of $96.1 million in Q1 2022, improving from a $172.9 million loss in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary

Coherus BioSciences, Inc. (NASDAQ: CHRS) has appointed Charlie Newton, a notable biotech strategist and CFO, to its Board of Directors. With nearly three decades of experience in healthcare investment banking, Newton is expected to enhance Coherus' immuno-oncology strategy. CEO Denny Lanfear recognizes his expertise in building shareholder value. Coherus is focusing on capitalizing on its commercial portfolio and advancing its pipeline, including a resubmission of a BLA for toripalimab to treat advanced nasopharyngeal carcinoma by mid-summer 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.26%
Tags
management
Rhea-AI Summary

Coherus BioSciences (CHRS) announced on April 27, 2022, the granting of stock options to 13 new employees totaling 240,000 shares. The options have an exercise price of $9.28, matching the closing trading price on that date. Among the granted options, two Vice Presidents received 45,000 shares each, while another received 50,000 shares. The remaining 100,000 shares were allocated to ten non-officer employees. This initiative is part of the 2016 Employment Commencement Incentive Plan to attract new talents to the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
Rhea-AI Summary

Coherus BioSciences (Nasdaq: CHRS) and Junshi Biosciences announce the FDA's complete response letter (CRL) regarding their Biologics License Application (BLA) for toripalimab, aimed at treating advanced nasopharyngeal carcinoma (NPC). The CRL requests a quality process change, which both companies believe is manageable. They plan to resubmit the BLA by mid-summer 2022, followed by a six-month FDA review timeline. Inspections in China for FDA approval are delayed due to COVID-19 restrictions. If approved, toripalimab will be the first immuno-oncology agent for NPC in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
none
-
Rhea-AI Summary

Coherus BioSciences (Nasdaq: CHRS) has announced that its first quarter 2022 financial results will be released after market close on May 5, 2022. A conference call will follow at 4:30 p.m. ET, where management will discuss the results and provide a business update. The corrected press release highlighted the new start time for the call, which was previously misstated. Interested parties can access the webcast and financial results on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
conferences earnings
Rhea-AI Summary

Coherus BioSciences (CHRS) will release its first quarter 2022 financial results on May 5, 2022, after market close. Following the announcement, management will host a conference call at 5 p.m. ET to discuss the results and provide a business update. Interested parties can access the call by dialing (844) 452-6826 for U.S. and Canadian callers or (765) 507-2587 internationally. A replay will be available on the company's website for 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
conferences earnings

FAQ

What is the current stock price of Coherus BioSciences (CHRS)?

The current stock price of Coherus BioSciences (CHRS) is $1.31 as of January 22, 2025.

What is the market cap of Coherus BioSciences (CHRS)?

The market cap of Coherus BioSciences (CHRS) is approximately 164.1M.

What does Coherus BioSciences specialize in?

Coherus BioSciences specializes in developing high-quality biosimilar therapeutics and innovative immuno-oncology therapies to treat chronic and life-threatening diseases.

Where is Coherus BioSciences headquartered?

Coherus BioSciences is headquartered in the San Francisco Bay Area.

What are some of Coherus' FDA-approved products?

Coherus markets UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), along with LOQTORZI™ (toripalimab-tpzi), a PD-1 inhibitor.

What recent transactions has Coherus BioSciences completed?

Coherus recently sold its CIMERLI® ophthalmology franchise to Sandoz, Inc. for $170 million.

How does Coherus BioSciences fund its immuno-oncology research?

Coherus leverages revenue generated from its diversified portfolio of FDA-approved biosimilars to fund its immuno-oncology research.

What is the significance of Coherus' partnership with the Cancer Research Institute?

The Cancer Research Institute has selected LOQTORZI for studies on drug-resistant cancers, highlighting the potential of Coherus' immuno-oncology treatments to advance patient care.

Which markets do Coherus' partnerships cover?

Coherus has commercialization partnerships with global pharmaceutical companies in Europe, Asia, and Latin America.

What recent achievements has Coherus made in its clinical pipeline?

Coherus presented promising preclinical data for CHS-1000 at the 2024 AACR Annual Meeting, demonstrating its potential to reverse tumor immunosuppression.

Who are the key figures in Coherus BioSciences' leadership?

Coherus is led by a team of industry veterans with decades of experience in pioneering biologics companies, including Chairman and CEO Denny Lanfear.

What is the focus of Coherus' CHS-114 clinical trials?

CHS-114, an anti-CCR8 antibody, is being evaluated in Phase 1 trials for its ability to selectively deplete tumor-resident regulatory T cells, enhancing anti-tumor immune response.
Coherus BioSciences, Inc.

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

164.06M
110.60M
1.38%
70.28%
26.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
REDWOOD CITY